Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology

Journal of Chemotherapy

Volumn 24, Issue 1, 2012, Pages 18-25

  Szilágyi, Judit ^a   Földi, Richárd ^a   Bayegan, Sedigh ^a   Kardos, Gábor ^a   Majoros, László ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Combination of nikkomycin Z and caspofungin; Human serum; Paradoxical growth

Indexed keywords

CASPOFUNGIN; NIKKOMYCIN Z;

ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; INOCULATION; METHODOLOGY; NONHUMAN; SERUM; TIME KILL METHODOLOGY;

AMINOGLYCOSIDES; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; SERUM; TIME FACTORS;

EID: 84866259916     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1120009X12Z.0000000005     Document Type: Article

References (32)

1. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46(1): 150-6.
2. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother. 2004;48(9):3407-11.
3. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother. 2007;51(6):2257-9.
4. Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother. 2006;50(4):1293-7.
5. Fleischhacker M, Radecke C, Schulz B, Ruhnke M. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J. Clin Microbiol Infect Dis. 2008;27(2):127-31.
6. Bizerra FC, Melo ASA, Katchburian E, Freymuller E, Straus AH, Takahashi HK, et al. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob Agents Chemother. 2011;55(1):302-10.
7. Sóczó G, Kardos G, Varga I, Kelentey B, Gesztelyi R, Majoros L. In vitro studies with Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin. Antimicrob Agents Chemother. 2007;51(12):4474-6.
8. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother. 2006;50(9):3160-1.
9. Varga I, Sóczó G, Kardos G, Kemény-Beke A, Kelentey B, Márton I, et al. Differences in killing activity of caspofungin and paradoxical growth between C. albicans and C. krusei clinical isolates in different media. J Chemother. 2009;21(1):36-41.
10. Shields RK, Nguyen MH, Du C, Press E, Cheng S, Clancy CJ. Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways, but eliminated in human serum. Antimicrob Agents Chemother. 2011;55(6): 2641-7.
11. Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 2008;4:e1000040.
12. Cota JM, Grabinski JL, Talbert RL, Burgess DS, Rogers PD, Edlind TD, et al. Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin. Antimicrob Agents Chemother. 2008;52(3):1144-6.
13. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71(1):11-41.
14. Migoya EM, Mistry GC, Stone JA, Comisar W, Sun P, Norcross A, et al. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol. 2011;51(2):202-11.
15. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. Influence of test conditions on antifungal time-kill curve results: proposed for standardized methods. Antimicrob Agents Chemother. 1998;42(5):1207-12.
16. Varga I, Sóczó G, Kardos G, Borbély A, Szabó Z, Kemény-Beke A, et al. Comparison of killing activity of caspofungin against Candida parapsilosis, C. orthopsilosis and C. metapsilosis. J Antimicrob Chemother. 2008;62(6):1466-8.
17. Somogyvari F, Doczi I, Serly I, Ahmad S, Nagy E. Rapid discrimination between Candida albicans and Candida dubliniensis by using real-time polymerase chain reaction. Diag Microbiol Infect Dis. 2007;58(3):367-9.
18. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard-3rd edition, M27-A3. Wayne (PA): CLSI, 2008.
19. Nix DE, Swezey RR, Hector R, Galgiani JN. Pharmacokinetics of nikkomycin Z after single rising oral doses. Antimicrob Agents Chemother. 2009;53(6):2517-21.
20. Garcia-Effron G, Park S, Perlin DS. Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob Agents Chemother. 2011;55(5):2245-55.
21. Kiraz N, Dag I, Yamac M, Kiremitci A, Kasifoglu N, Oz Y. Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods. Antimicrob Agents Chemother. 2010;54(5):2244-7.
22. Wiederhold NP. Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. Curr Opin Infect Dis. 2007;20(6):574-8.
23. Bayegan S, Majoros L, Kardos G, Kemény-Beke A, Miszti C, Kovacs R, et al. In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in the presence of high concentration of caspofungin. J Microbiol. 2010;48(2):170-3.
24. Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother. 2006;50(4):1293-7.
25. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, et al. Caspofungin High-Dose Study Group. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48(12):1676-84.
26. Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, de Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883-93.
27. Shields RK, Nguyen MH, Press E, Clancy CJ. Five-minute exposure to caspofungin results in prolonged post-antifungal effects and eliminates the paradoxical growth of Candida albicans. Antimicrob Agents Chemother. 2011;55(7):3598-602.
28. Sandovsky-Losica H, Shwartzman R, Lahat Y, Segal E. Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B. J Antimicrob Chemother. 2008;62(3):635-7.
29. Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother. 1999;43(6):1401-5.
30. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011;14(3):164-76.
31. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-35.
32. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother. 2010;54(6):2497-506.